PPT-Sex and the Superbug: Next Steps in Dealing with Multi-drug Resistant Gonorrhea

in Maryland Khalil Ghanem MD PhD Associate Professor of Medicine Johns Hopkins University School of Medicine Director STDHIVTB Clinical Services Baltimore City Health Department October 4 2012. Prevention of spread and c ontrol of MD s in health care setting are critical and urgent as the number of antibiotic available to treat these infections is extremely limited and development of new antibiotics is not forthcoming in the foreseeable fu of Tuberculosis Internationally. Tuberculosis Control In Vulnerable Groups. Bulletin of the World Health Organization. TB is an in important public health problem in industrialized countries. Most cases occur in minority groups. Two examples provide evidence for natural selection: the effect of differential predation on guppy populations and the evolution of drug-resistant HIV. Copyright © 2008 Pearson Education, Inc., publishing as Pearson Benjamin Cummings. Next Steps in Dealing with Multi-drug Resistant Gonorrhea . in Maryland. Khalil Ghanem, MD, PhD. Associate Professor of Medicine. Johns Hopkins University School of Medicine. Director, STD/HIV/TB Clinical Services. of Tuberculosis Internationally. Tuberculosis Control In Vulnerable Groups. Bulletin of the World Health Organization. TB is an in important public health problem in industrialized countries. Most cases occur in minority groups. S. . aureus. Chloe Jones. Loyola Marymount University . BIOL368: Bioinformatics Laboratory. October 28, 2014. . Outline . MRSA infections rising due to resistant strains. Antimicrobial peptides, a potential source to combat resistant bacteria. Akujobi. CN, . Okoro. CE, . Anyabolu. AE, . Okonkwo. RC, . Onwunzo. MC and . Chukwuka. CP. Tuberculosis (TB) is the most common opportunistic infection in Human . Immuno. d. eficiency . Virus (HIV. 31e Costly Burden of Drug-Resistant TB Disease in the USverage treatment costs per case 2018 dollarsMultidrug-resistant MDR tuberculosis disease is a major health threat globally Nearly half a million [NAME OF PRESENTER]. [TITLE OF PRESENTER]. STREAM Clinical Trial. Overview of the presentation. Outline. Burden of disease. TB treatments. Conclusions. Status of MDR TB in the world. Status of MDR/RR-TB . NAME. TITLE. DATE (Optional). PATH/Rocky . Prajapati. Typhoid burden. Typhoid continues to be a substantial public health threat that disproportionately impacts children and marginalized populations in much of Asia and sub-Saharan Africa.. 1.BackgroundofresearchThereisanemergenceofmultidrugresistantbacteriawhichareunabletotreatwithmultipleantibacterialdrugs.Multidrugresistantbacterialinfectionsarebecominganimportantproblemfacinghealthca — 91 — and extensively drug resistant TB — 92 — and extensively drug resistant TBficient anti TB programs were the most affected by multi-resistance. Global resistance figures prov Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale B Southeast Asia, east Asia and Oceania. High income. Latin America and Caribbean. Central Europe, eastern Europe and central Asia. South Asia. Sub-Saharan Africa. Antimicrobial resistance (AMR): . Deaths .